Arlene Naranjo1, Meredith S Irwin1, Michael D Hogarty1, Susan L Cohn1, Julie R Park1, Wendy B London1. 1. Arlene Naranjo, University of Florida, Gainesville, FL; Meredith S. Irwin, Hospital for Sick Children, Toronto, ON, Canada; Michael D. Hogarty, University of Pennsylvania, Philadelphia, PA; Susan L. Cohn, The University of Chicago, Chicago, IL; Julie R. Park, University of Washington, Seattle, WA; and Wendy B. London, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA.
Abstract
PURPOSE: The International Neuroblastoma Risk Group (INRG) Staging System (INRGSS) was developed through international consensus to provide a presurgical staging system that uses clinical and imaging data at diagnosis. A revised Children's Oncology Group (COG) neuroblastoma (NB) risk classification system is needed to incorporate the INRGSS and within the context of modern therapy. Herein, we provide statistical support for the clinical validity of a revised COG risk classification system. PATIENTS AND METHODS: Nine factors were tested for potential statistical and clinical significance in 4,569 patients diagnosed with NB who were enrolled in the COG biology/banking study ANBL00B1 (2006-2016). Recursive partitioning was performed to create a survival-tree regression (STR) analysis of event-free survival (EFS), generating a split by selecting the strongest prognostic factor among those that were statistically significant. The least absolute shrinkage and selection operator (LASSO) was applied to obtain the most parsimonious model for EFS. COG patients were risk classified using STR, LASSO, and per the 2009 INRG classification (generated using an STR analysis of INRG data). Results were descriptively compared among the three classification approaches. RESULTS: The 3-year EFS and overall survival (± SE) were 72.9% ± 0.9% and 84.5% ± 0.7%, respectively (N = 4,569). In each approach, the most statistically and clinically significant factors were diagnostic category (eg, NB, ganglioneuroblastoma), INRGSS, MYCN status, International Neuroblastoma Pathology Classification, ploidy, and 1p/11q status. The results of the STR analysis were more concordant with those of the INRG classification system than with LASSO, although both methods showed moderate agreement with the INRG system. CONCLUSION: These analyses provide a framework to develop a new COG risk classification incorporating the INRGSS. There is statistical evidence to support the clinical validity of each of the three classifications: STR, LASSO, and INRG.
PURPOSE: The International Neuroblastoma Risk Group (INRG) Staging System (INRGSS) was developed through international consensus to provide a presurgical staging system that uses clinical and imaging data at diagnosis. A revised Children's Oncology Group (COG) neuroblastoma (NB) risk classification system is needed to incorporate the INRGSS and within the context of modern therapy. Herein, we provide statistical support for the clinical validity of a revised COG risk classification system. PATIENTS AND METHODS: Nine factors were tested for potential statistical and clinical significance in 4,569 patients diagnosed with NB who were enrolled in the COG biology/banking study ANBL00B1 (2006-2016). Recursive partitioning was performed to create a survival-tree regression (STR) analysis of event-free survival (EFS), generating a split by selecting the strongest prognostic factor among those that were statistically significant. The least absolute shrinkage and selection operator (LASSO) was applied to obtain the most parsimonious model for EFS. COG patients were risk classified using STR, LASSO, and per the 2009 INRG classification (generated using an STR analysis of INRG data). Results were descriptively compared among the three classification approaches. RESULTS: The 3-year EFS and overall survival (± SE) were 72.9% ± 0.9% and 84.5% ± 0.7%, respectively (N = 4,569). In each approach, the most statistically and clinically significant factors were diagnostic category (eg, NB, ganglioneuroblastoma), INRGSS, MYCN status, International Neuroblastoma Pathology Classification, ploidy, and 1p/11q status. The results of the STR analysis were more concordant with those of the INRG classification system than with LASSO, although both methods showed moderate agreement with the INRG system. CONCLUSION: These analyses provide a framework to develop a new COG risk classification incorporating the INRGSS. There is statistical evidence to support the clinical validity of each of the three classifications: STR, LASSO, and INRG.
Authors: J G Gurney; J A Ross; D A Wall; W A Bleyer; R K Severson; L L Robison Journal: J Pediatr Hematol Oncol Date: 1997 Sep-Oct Impact factor: 1.289
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: A T Look; F A Hayes; J J Shuster; E C Douglass; R P Castleberry; L C Bowman; E I Smith; G M Brodeur Journal: J Clin Oncol Date: 1991-04 Impact factor: 44.544
Authors: H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry Journal: Cancer Date: 1999-07-15 Impact factor: 6.860
Authors: Veronica Moroz; David Machin; Andreas Faldum; Barbara Hero; Tomoko Iehara; Veronique Mosseri; Ruth Ladenstein; Bruno De Bernardi; Hervé Rubie; Frank Berthold; Katherine K Matthay; Tom Monclair; Peter F Ambros; Andrew D J Pearson; Susan L Cohn; Wendy B London Journal: Eur J Cancer Date: 2010-11-26 Impact factor: 9.162
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Daria Thompson; Kieuhoa T Vo; Wendy B London; Matthias Fischer; Peter F Ambros; Akira Nakagawara; Garrett M Brodeur; Katherine K Matthay; Steven G DuBois Journal: Cancer Date: 2015-12-28 Impact factor: 6.860
Authors: Yaël P Mossé; Rebecca J Deyell; Frank Berthold; Akira Nagakawara; Peter F Ambros; Tom Monclair; Susan L Cohn; Andrew D Pearson; Wendy B London; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2013-09-13 Impact factor: 3.167
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Elizabeth Sokol; Ami V Desai; Mark A Applebaum; Dominique Valteau-Couanet; Julie R Park; Andrew D J Pearson; Gudrun Schleiermacher; Meredith S Irwin; Michael Hogarty; Arlene Naranjo; Samuel Volchenboum; Susan L Cohn; Wendy B London Journal: J Clin Oncol Date: 2020-04-21 Impact factor: 44.544
Authors: Wayne H Liang; Sara M Federico; Wendy B London; Arlene Naranjo; Meredith S Irwin; Samuel L Volchenboum; Susan L Cohn Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Emily Hibbitts; Yueh-Yun Chi; Douglas S Hawkins; Frederic G Barr; Julie A Bradley; Roshni Dasgupta; William H Meyer; David A Rodeberg; Erin R Rudzinski; Sheri L Spunt; Stephen X Skapek; Suzanne L Wolden; Carola A S Arndt Journal: Cancer Med Date: 2019-08-27 Impact factor: 4.452
Authors: Meredith S Irwin; Arlene Naranjo; Fan F Zhang; Susan L Cohn; Wendy B London; Julie M Gastier-Foster; Nilsa C Ramirez; Ruthann Pfau; Shalini Reshmi; Elizabeth Wagner; Jed Nuchtern; Shahab Asgharzadeh; Hiroyuki Shimada; John M Maris; Rochelle Bagatell; Julie R Park; Michael D Hogarty Journal: J Clin Oncol Date: 2021-07-28 Impact factor: 50.717